Basic Information

              Yan Wang

     Ph.D., Associate Researcher
          Ph.D. Supervisor
Deputy Director, Department of Pharmacy, Second Affiliated Hospital of Xi'an Jiaotong University

E-mail: wangyan0819@mail.xjtu.edu.cn

Educational Experience

2013 – 2018，Ph.D., Clinical Pharmacy, Medical Department, Xi'an Jiaotong University, China. Supervisor: Dong Yalin

2017– 2018, Joint Ph.D. Program, Pharmacoepidemiology, School of Pharmacy, University of Queensland, Australia. Supervisor: Mieke van Driel

2009 – 2013, Bachelor’s Degree, School of Pharmacy, Southwest University, China

Research Fields

Research Focus

Optimizing antimicrobial therapy in critically ill patients

  • Pharmacoepidemiology (Evidence-Based Pharmacy and Pharmacoeconomics)
  • Data Mining in Databases of Critically Ill Patients
  • Machine Learning Methods and Biomedical Big Data of Critically Ill Patients

Personal Biography

Principal investigator for two projects funded by the National Natural Science Foundation of China (Grant No. 72274153,  71904155)

Additionally, awarded one Provincial Key R&D Plan, one Provincial Innovation Capacity Support Plan, and selected as one of the first batch of "Yuying Plan - Rising Stars" at the Second Affiliated Hospital of Xi'an Jiaotong University (one of six hospital-wide). Principal investigator for three other vertical research projects, with current research funding exceeding 2.8 million RMB.

Published 46 SCI papers, with 17 as first or corresponding author (including 9 in Q1 journals and 1 highly cited paper by ESI).

Honors

  • Shaanxi Provincial Climbing Program for Innovative Talent -2024 "Young Science and Technology Star"
  • "Zhongying Young Scholar" of Xi’an Jiaotong University
  • "Yuying Program" of The Second Affiliated Hospital of Xi’an Jiaotong University

Publications

  1. Liu Y, Dai M, Zhang K, Zhang L, Lin B, Chen K, Wang H, Gu Z, Yu Y, Wang Yan*. Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data. Int J Antimicrob Agents. 2024 Jul 31;64(4):107288.（Q2）
  2. Zhang Li, Li Ping, Liu Chenwei, Zheng Qiwen, Wang Yan*. Low early anti-factor Xa target achievement rate of low molecular weight heparin for treating venous thromboembolism in intensive care unit patients. J Clin Pharmacol. 2023 Jun;63(6):664-671.
  3. Xing Yuanming, Qiu Yulan, Yang Luting, Yuan Zuyi, Wang Yan *. Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. Int J Cardiol. 2023 Jan 15;371:420-426.（Q2）
  4. Xie J, Yang Q, Han X, Dong Y, Zhang T, Li Y, Ji M, Liu C, Cai Y, Wang Y*. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: A Step toward Dose Optimization Using Monte Carlo Simulation. Antimicrob Agents Chemother. 2022 Jun 21;66(6): e0009922; （Q1）
  5. Wang Y*, Mieke L Van Driel, Treasure M McGuire, Samantha A Hollingworth. Trends in systemic antifungal use in Australia, 2005-2016: a time-series analysis. Jpn J Infect Dis. 2022 May 24;75(3):254-261;
  6. Han R, Teng M, Zhang Y, Zhang T, Wang T, Chen J, Li S, Yang B, Shi Y, Dong Y*, Wang Y*. Choosing Optimal Antibiotics for the Treatment of Patients Infected With Enterobacteriaceae: A Network Meta-analysis and Cost-Effectiveness Analysis. Front Pharmacol. 2021 Jun 17; 12:656790; （Q2）
  7. Wang Y, Zhang Y, TM McGuire, SA Hollingworth, ML Van Driel, Cao L, Wang X, Dong Y*. ICU patients' antibiotic exposure and triazole-resistance in invasive candidiasis: parallel analysis of aggregated and individual data. Front Pharmacol. 2021 Mar 22; 12:586893;（Q2）
  8. Wang Y#*, Zhong H#, Han X, Wang N, Cai Y, Wang H, Yu J, Zhang X, Zhang K*. Impact of antibiotic prescription on the resistance of Klebsiella pneumoniae at a tertiary hospital in China, 2012-2019. Am J Infect Control. 2021, 49(1): 65-69;
  9. Wang Y*, Treasure M McGuire, Samantha A Hollingworth, Dong Y, Mieke L Van Driel. Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: what do the guidelines recommend? Int J Infect Dis. 2019, 89: 137-145;（Q2）
  10. Wang Y, Xing Y, Chen L, Meng T, Li Y, Xie J, Chen L, Dong Y*, Dong W*. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis. Int J Hematology, 2018, 107(2): 235-243；
  11. Wang Y, Xie J, Xing Y, Chen L, Li Y, Meng T, Dong W, Wang X, Dong Y*. Choosing optimal antifungal agents to prevent fungal infections in nonneutropenic critically ill patients: trial sequential analysis, network meta-analysis, and pharmacoeconomic analysis. Antimicrob Agents Chemother, 2017, 61(12): e00620-17；（Q1）
  12. Wang Y, Yang Q, Chen L, Liu L, Hao R, Zhang T, Wang X, Lei J, Xie J, Dong Y*. Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study. Eur J Clin Microbiol Infect Dis, 2017, 36(11): 2117-2126；
  13. Wang Y, Wang T, Xie J, Yang Q, Zheng X, Dong W, Xing J, Wang X, Dong Y*. Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit. Pharmacotherapy, 2016, 36(7): 757-765;（Q2）
  14. Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, Dong W, Xing J, Dong Y*. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol, 2015, 71(1): 107-115；
  15. Zhong H#, Wang Y#, Zhang Z, Liu Y, Le K, Cui M, Yu Y*, Gu Z*, Gao Y, Lin H*. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol Res. 2020, 157: 104872；（Q1）
  16. Zhang Y#, Wang Y#, Van Driel ML, McGuire TM, Zhang T, Dong Y, Liu Y, Liu L, Hao R, Cao L, Xing J, Dong Y*. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control, 2019, 8:72.（Q2）
  17. Zhang Li#, Wang Yan#, Ping Li, Wang Haitao, Cai Yan, Wang Na, Liu Chenwei, Fang Yu*. Impact of clinical pharmacist services on physicians' guideline compliance and prognosis of patients for venous thromboembolism prophylaxis in ICU. Int J Clin Pharmacol Ther. 2023 Jan;61:24-32.